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ABSTRACT 
 
Background: This study aimed to compare the morbidity and disease free pro-
gression between patients with advanced ovarian cancer treated with neoadjuvant 
chemotherapy (NAC) followed by surgery and those treated conventionally with 
cytoreductive surgery followed by cytotoxic chemotherapy. 
Subjects and method: This was a retrospective-cohort study conducted at Dr. 
Cipto Mangunkusumo Hospital, Jakarta. A sample of 84 patients with advanced-
stage ovarian cancer was selected for this study, consisting of 64 patients treated 
conventionally (CT group) with primary surgery followed by platinum-based adju-
vant chemotherapy, 20 patients treated with neoadjuvant chemotherapy, of which 
8 patients subsequently underwent interval debulking and adjuvant chemotherapy 
(NAC group). The dependent variables were morbidity and disease free 
progression. The independent data were neoadjuvant chemotherapy and cyto-
reductive surgery followed by cytotoxic chemotherapy. The data were collected 
from medical record and questionnaire. Difference in means between the two 
groups was tested by t-test. Difference in percents between the two groups was tes-
ted by chi-square. 
Results: The response rate to the NAC assessed at three cycles was 40%. 
Performance status (Hb, albumin, ascites, pleural effusion, Ca 125, and stage) in 
the NAC group was worse than CT group.  Disease free progression after 12 and 24 
months in the NAC group was 30% and 5%, CT group was 10% and 7.5%, respecti-
vely. Parameters of surgical aggressiveness (massive bleeding, organ injury, and 
ICU stay) were lower in the NAC group than the conventional group. Complication 
rate of surgical injury in CT group was 17% and zero in the NAC group.  
Conclusion: Neoadjuvant chemotherapy followed by interval debulking in advan-
ced ovarian cancer does not affect disease free progression but reduces morbidity. 
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